DPP10-AS1: A Potential Drug Target and Biomarker for Antisense Therapies

Target Name: DPP10-AS1

NCBI ID: G389023

DPP10-AS1

Other Name(s): DPP10 antisense RNA 1

DPP10-AS1: A Potential Drug Target and Biomarker for Antisense Therapies

Development of new therapeutic approaches for diseases is a continuous process, and the discovery of small molecules that can inhibit specific pathways has become a significant area of research in recent years. One of the promising strategies is the use of antisense drugs, which are small molecules that bind to a specific protein and inhibit its function. In this article, we will focus on one such molecule, DPP10-AS1 (DPP10 antisense RNA 1), which has the potential to be a drug target or biomarker for antisense therapies.

DPPA: The Natural Antisense Pathway

DPP10 (doublestranded RNA phosphatase) is a key enzyme in the doublestranded RNA (dsRNA) pathway, which is responsible for the elimination of non-coding RNAs in the cell. Mutations in the DPP10 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The normal function of DPP10 is to recognize and remove doublestranded RNA residues from the RNA molecule, allowing for the translation of specific genes.

In addition to its role in RNA homeostasis, DPP10 has also been shown to play a critical role in the development and progression of cancer. DPP10 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. It has also been shown to promote the translation of oncogenes and tumor suppressor genes, thereby contributing to the development of cancer.

antisense therapies: A Review

Antisense therapies are a class of drugs that work by binding to a specific protein and inhibiting its function. These drugs have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the fundamental principles of antisense therapies is the use of small molecules that can specifically bind to a protein. These small molecules are called antisense oligonucleotides (ASOs) or antisense DNA/RNA probes. ASOs can be designed to target specific amino acid residues, codons, or RNA structures within the target protein.

DPP10-AS1: A Potential Drug Target

The discovery of DPP10-AS1 (DPP10 antisense RNA 1) provides a new potential drug target for antisense therapies. DPP10-AS1 is a small molecule that binds to the protein DPP10, which is involved in the regulation of cell cycle progression, apoptosis, and angiogenesis.

In cellular signaling pathways, DPP10 plays a critical role in the regulation of cell cycle progression, which is the process by which cells divide and grow. DPP10 is shown to be involved in the regulation of the G1 phase of the cell cycle, as well as the G2 and M phases.

DPP10-AS1 has also been shown to play a critical role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. DPP10-AS1 has been shown to promote the translation of pro-apoptotic genes, such as Bcl-2 and p53, which are involved in the regulation of cell death.

DPP10-AS1 has also been shown to play a critical role in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. DPP10-AS1 has been shown to promote the translation of genes involved in angiogenesis, such as VEGF and Angiogenesis-associated protein 2 (AP-2).

DPP10-AS1: A Potential Biomarker

The identification of DPP10-AS1 as a potential drug target or biomarker for antisense therapies is significant because it provides new insights into the biology of DPP10 and its role in the development and progression of disease.

The use of DPP10-AS1 as an

Protein Name: DPP10 Antisense RNA 1

The "DPP10-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPP10-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets